This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2010 Apr 1;116(7):1623-5.

doi: 10.1002/cncr.24909.

Tumor progression by immune evasion in melanoma: role of the programmed cell death-1/programmed cell death-1 ligand 1 interaction

Mohammed Kashani-Sabet

PMID: 20143442
DOI: 10.1002/cncr.24909

Free article

Editorial

Tumor progression by immune evasion in melanoma: role of the programmed cell death-1/programmed cell death-1 ligand 1 interaction

Mohammed Kashani-Sabet. Cancer. 2010.

Free article

. 2010 Apr 1;116(7):1623-5.

doi: 10.1002/cncr.24909.

Author

Mohammed Kashani-Sabet

PMID: 20143442
DOI: 10.1002/cncr.24909

No abstract available

PubMed Disclaimer

Comment on

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.
Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, Honjo T, Okazaki T, Tokura Y. Hino R, et al. Cancer. 2010 Apr 1;116(7):1757-66. doi: 10.1002/cncr.24899. Cancer. 2010. PMID: 20143437

Similar articles

Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes.
Chapon M, Randriamampita C, Maubec E, Badoual C, Fouquet S, Wang SF, Marinho E, Farhi D, Garcette M, Jacobelli S, Rouquette A, Carlotti A, Girod A, Prévost-Blondel A, Trautmann A, Avril MF, Bercovici N. Chapon M, et al. J Invest Dermatol. 2011 Jun;131(6):1300-7. doi: 10.1038/jid.2011.30. Epub 2011 Feb 24. J Invest Dermatol. 2011. PMID: 21346771
PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.
Shi F, Shi M, Zeng Z, Qi RZ, Liu ZW, Zhang JY, Yang YP, Tien P, Wang FS. Shi F, et al. Int J Cancer. 2011 Feb 15;128(4):887-96. doi: 10.1002/ijc.25397. Int J Cancer. 2011. PMID: 20473887
PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients.
Kozako T, Yoshimitsu M, Fujiwara H, Masamoto I, Horai S, White Y, Akimoto M, Suzuki S, Matsushita K, Uozumi K, Tei C, Arima N. Kozako T, et al. Leukemia. 2009 Feb;23(2):375-82. doi: 10.1038/leu.2008.272. Epub 2008 Oct 2. Leukemia. 2009. PMID: 18830259
Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways.
Wang S, Chen L. Wang S, et al. Curr Top Microbiol Immunol. 2011;344:245-67. doi: 10.1007/82_2010_81. Curr Top Microbiol Immunol. 2011. PMID: 20582531 Review.
Programmed death-1 & its ligands: promising targets for cancer immunotherapy.
Shrimali RK, Janik JE, Abu-Eid R, Mkrtichyan M, Khleif SN. Shrimali RK, et al. Immunotherapy. 2015;7(7):777-92. doi: 10.2217/imt.15.49. Epub 2015 Aug 7. Immunotherapy. 2015. PMID: 26250412 Review.

See all similar articles

Cited by

Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas.
de Moll EH, Fu Y, Qian Y, Perkins SH, Wieder S, Gnjatic S, Remark R, Bernardo SG, Moskalenko M, Yao J, Ferringer T, Chang R, Chipuk J, Horst BA, Birge MB, Phelps RG, Saenger YM. de Moll EH, et al. Cancer Immunol Immunother. 2015 Sep;64(9):1193-203. doi: 10.1007/s00262-015-1726-0. Epub 2015 Jun 16. Cancer Immunol Immunother. 2015. PMID: 26076664 Free PMC article.
PD-1 and cancer: molecular mechanisms and polymorphisms.
Salmaninejad A, Khoramshahi V, Azani A, Soltaninejad E, Aslani S, Zamani MR, Zal M, Nesaei A, Hosseini SM. Salmaninejad A, et al. Immunogenetics. 2018 Feb;70(2):73-86. doi: 10.1007/s00251-017-1015-5. Epub 2017 Jun 22. Immunogenetics. 2018. PMID: 28642997 Review.
Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages.
Yao X, Tu Y, Xu Y, Guo Y, Yao F, Zhang X. Yao X, et al. J Cell Mol Med. 2020 Sep;24(17):9560-9573. doi: 10.1111/jcmm.15367. Epub 2020 Jul 16. J Cell Mol Med. 2020. PMID: 32672418 Free PMC article.
PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation.
Ji M, Liu Y, Li Q, Li XD, Zhao WQ, Zhang H, Zhang X, Jiang JT, Wu CP. Ji M, et al. J Transl Med. 2015 Jan 16;13:5. doi: 10.1186/s12967-014-0373-0. J Transl Med. 2015. PMID: 25592115 Free PMC article. Review.
The modulation of Dicer regulates tumor immunogenicity in melanoma.
Hoffend NC, Magner WJ, Tomasi TB. Hoffend NC, et al. Oncotarget. 2016 Jul 26;7(30):47663-47673. doi: 10.18632/oncotarget.10273. Oncotarget. 2016. PMID: 27356752 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program